Helsinn Grants to DARA BioSciences, Inc. Exclusive U.S. Commercial Rights to Gelclair®, an FDA-Cleared Oral Gel for the Treatment of Oral Mucositis
LUGANO, Switzerland & RALEIGH, N.C.--(BUSINESS WIRE)--The Helsinn Group of Switzerland announced today that it has entered into an exclusive agreement with DARA BioSciences, Inc. (Nasdaq: DARA) for U.S. commercial rights to Gelclair®. Gelclair is an FDA-cleared product indicated for the treatment of oral mucositis. DARA plans to launch Gelclair in the first quarter of 2013.